Merck (MRK) earnings Q4 2025

Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later Continue Reading

Pfizer (PFE) earnings Q4 2025

Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026. Oscar Molina | CNBC Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance Continue Reading

PepsiCo (PEP) Q4 2025 earnings

Packages of Pepsi are displayed on a store shelf on Oct. 9, 2025 in San Anselmo, California. Justin Sullivan | Getty Images PepsiCo on Tuesday reported quarterly earnings and revenue that topped analysts’ expectations, fueled by improving organic sales across its business. Demand for the company’s snacks has been sluggish as consumers Continue Reading